Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters
L Pekka Malmberg1, Paula Rytilä2, Pertti Happonen2, Tari Haahtela1
1Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland; 2Orion Corporation, Orion Pharma, Espoo, Finland
Background: Dry powder inhalers (DPIs) are inspiratory flow driven and hence flow dependent. Most patients with chronic obstructive pulmonary disease (COPD) are elderly and have poor lung function. The factors affecting their inspiratory flows through inhalers are unclear.
Objective: To study peak inspiratory flows (PIFs) and their determinants through a DPI in COPD patients of varying age and severity.
Methods: Flow-volume spirometry was performed in 93 COPD patients. Maximum PIF rates were recorded through an empty Easyhaler® (PIFEH; Orion Corporation, Espoo, Finland), a DPI that provides consistent dose delivery at inhalation rates through the inhaler of 28 L/min or higher.
Results: The mean PIFEH was 54 L/min (range 26–95 L/min) with a coefficient of variation of 7%. All but two patients were able to generate a flow of ≥28 L/min. In a general linear model, the independent determinants for PIFEH were age (P = 0.02) and gender (P = 0.01), and forced expiratory volume in 1 s (FEV1) expressed as percent predicted was not a significant factor. The regression model accounted only for 18% of the variation in PIFEH.
Conclusion: In patients with COPD, age and gender are more important determinants of inspiratory flow through DPIs than the degree of expiratory airway obstruction. Most COPD patients with varying age and severity are able to generate inspiratory flows through the test inhaler that is sufficient for optimal drug delivery to the lower airways.
Keywords: COPD, forced expiratory volume, peak inspiratory flow
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Heike Rau-Berger, Harald Mitfessel, Thomas Glaab
Published Date: 10 October 2010
Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease
Davood Attaran, Shahrzad M Lari, Mohammad Towhidi, et al
Published Date: 30 September 2010
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
Beatrix Balint, Henrik Watz, Carolynn Amos, et al
Published Date: 6 September 2010
Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease
John A Marwick, Kian Fan Chung
Published Date: 1 September 2010
Nicholas J Gross, James F Donohue
Published Date: 28 June 2010
A Catherine Simpson, Joanne Young, Margaret Donahue, et al
Published Date: 10 May 2010
Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD
Joseph Seaman, Anthony C Leonard, Ralph J Panos
Published Date: 31 March 2010
Tillie L Hackett, Darryl A Knight, Don D Sin
Published Date: 26 March 2010
Published Date: 9 March 2010
Donald P Tashkin
Published Date: 18 February 2010